153 related articles for article (PubMed ID: 11295089)
1. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules.
Berrak SG; Ewer MS; Jaffe N; Pearson P; Ried H; Zietz HA; Benjamin RS
Oncol Rep; 2001; 8(3):611-4. PubMed ID: 11295089
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.
Ewer MS; Jaffe N; Ried H; Zietz HA; Benjamin RS
Med Pediatr Oncol; 1998 Dec; 31(6):512-5. PubMed ID: 9835904
[TBL] [Abstract][Full Text] [Related]
4. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
Legha SS; Benjamin RS; Mackay B; Ewer M; Wallace S; Valdivieso M; Rasmussen SL; Blumenschein GR; Freireich EJ
Ann Intern Med; 1982 Feb; 96(2):133-9. PubMed ID: 7059060
[TBL] [Abstract][Full Text] [Related]
5. Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography.
Gillings S; Johnson J; Fulmer A; Hauck M
Vet Ther; 2009; 10(1-2):46-58. PubMed ID: 19742448
[TBL] [Abstract][Full Text] [Related]
6. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for doxorubicin-induced congestive heart failure.
Von Hoff DD; Layard MW; Basa P; Davis HL; Von Hoff AL; Rozencweig M; Muggia FM
Ann Intern Med; 1979 Nov; 91(5):710-7. PubMed ID: 496103
[TBL] [Abstract][Full Text] [Related]
8. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
Lipshultz SE; Miller TL; Lipsitz SR; Neuberg DS; Dahlberg SE; Colan SD; Silverman LB; Henkel JM; Franco VI; Cushman LL; Asselin BL; Clavell LA; Athale U; Michon B; Laverdière C; Schorin MA; Larsen E; Usmani N; Sallan SE;
Pediatrics; 2012 Dec; 130(6):1003-11. PubMed ID: 23166343
[TBL] [Abstract][Full Text] [Related]
9. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion.
Huh WW; Jaffe N; Durand JB; Munsell MF; Herzog CE
Pediatr Hematol Oncol; 2010 Oct; 27(7):546-57. PubMed ID: 20795769
[TBL] [Abstract][Full Text] [Related]
10. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
11. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
12. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography.
Agarwala S; Kumar R; Bhatnagar V; Bajpai M; Gupta DK; Mitra DK
J Pediatr Surg; 2000 Dec; 35(12):1786-9. PubMed ID: 11101737
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.
Mitani I; Jain D; Joska TM; Burtness B; Zaret BL
J Nucl Cardiol; 2003; 10(2):132-9. PubMed ID: 12673177
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
16. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation.
Shapira J; Gotfried M; Lishner M; Ravid M
Cancer; 1990 Feb; 65(4):870-3. PubMed ID: 2297656
[TBL] [Abstract][Full Text] [Related]
17. Prevention of doxorubicin-induced congestive heart failure by continuous intravenous infusion in multiple myeloma; a case report and review of the literature.
Lieverse RJ; Ossenkoppele GJ
Neth J Med; 1991 Feb; 38(1-2):33-4. PubMed ID: 2030807
[TBL] [Abstract][Full Text] [Related]
18. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.
Green DM; Grigoriev YA; Nan B; Takashima JR; Norkool PA; D'Angio GJ; Breslow NE
J Clin Oncol; 2001 Apr; 19(7):1926-34. PubMed ID: 11283124
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
[TBL] [Abstract][Full Text] [Related]
20. Serial studies of cardiac function in patients receiving adriamycin.
Henderson IC; Sloss LJ; Jaffe N; Blum RH; Frei E
Cancer Treat Rep; 1978 Jun; 62(6):923-9. PubMed ID: 667869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
